Regarding the tumor subtypes in our cohort, 42 patients (27.8%) had luminal B/Her2-negative, 36 (23.8%) luminal B/Her2-positive, 56 (37.1%) triple-negative, and 17 (11.3%) Her2-enriched subtype tumors. The gene discussed is ERBB2; the disease is neoplasm.